ArticlePeerJ2025
Protein composition analysis of human plasma-derived and recombinant human serum albumin preparations based on 4D label-free proteomics.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative Characterisation of Five Plasma-Derived Human Serum Albumin Preparations: Structural Integrity, Functional Properties, and Quality Attributes.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The problem lies in the medium: challenges for diagnostic use of spent culture media in IVF.Frontiers in reproductive health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical therapeutic human serum albumin (HSA) preparations are typically derived from human plasma and contain various accompanying proteins (APs). Previous studies have documented extensively the disparities in post-translation modifications, redox states and antioxidant capacities among HSA preparations from different manufacturers. Most of these studies have focused primarily on albumin, and analyzing APs in HSA preparations and recombinant HSA (rHSA) was often neglected. Methods: In this study, the APs in human plasma-derived HSA (pHSA) from six Chinese manufacturers and recombinant HSA (rHSA) from yeast and rice were identified and analyzed using a four-dimensional (4D) label-free quantitative proteomic technology. Results: A total of 456 different APs from the six pHSA preparations were identified, with 96 APs consistently detected in all pHSA samples. 52 APs from yeast-produced rHSA were identified, whereas 152 APs were detected in rice-expressed rHSA. Among the detected APs, haptoglobin, hemopexin and transthyretin were among the top eight APs with the highest relative abundance consistently observed in all pHSA preparations. Moreover, the results revealed that the identified APs in pHSA are primarily involved in endopeptidase inhibitor activity, complement and coagulation cascades, biosynthesis of amino acids and cholesterol metabolism by Gene Ontology (GO), Clusters of Orthologous Groups (COG)/euKaryotic Orthologous Groups (KOG), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interactions (PPI) annotation. The ELISA validation results confirmed the presence of haptoglobin, hemopexin, transthyretin and serotransferrin in pHSA but not in rHSA, aligning with the findings from the 4D label-free quantitative proteomic analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.